OncoSil Medical (ASX:OSL) presented interim results from the OSPREY Registry at ESGE Days 2026, reporting encouraging real-world safety and efficacy outcomes for patients with unresectable locally advanced pancreatic cancer treated with EUS-guided phosphorus-32 microparticles in combination with gemcitabine-based chemotherapy.
The analysis, based on 64 patients enrolled across Austria, Greece, Italy and Spain, with total enrolment now exceeding 80 patients, found adverse device effects in 15.6 per cent of patients that were primarily mild Grade 1 abdominal pain and one Grade 2 fatigue event, with no Grade greater than or equal to 3 adverse device effects and no serious adverse device effects reported.
Local disease control at 12 weeks post-implant was 91.4 per cent in patients receiving first-line chemotherapy and 77.8 per cent in those receiving second-line chemotherapy. Seven patients went on to surgical resection with curative intent after OncoSil treatment, and five of those patients achieved R0 resection margins (complete microscopic removal of the tumour). Median overall survival in first-line chemotherapy patients was 20.6 months for those implanted within 4 months of starting chemotherapy and 22 months for those implanted between 4 and 12 months, outcomes the investigators noted compare favourably with historical benchmarks for gemcitabine plus nab-paclitaxel alone.
Nigel Lange, CEO and Managing Director of OncoSil Medical, said, "The presentation of the interim OSPREY Registry results at ESGE Days 2026 is another important milestone for OncoSil and provides further validation of the encouraging clinical outcomes previously observed in our earlier studies and clinical data. Importantly, these results demonstrate that the safety profile and efficacy outcomes associated with OncoSil can also be achieved in routine real-world clinical practice across multiple centres in Europe. Seeing consistent disease control, encouraging survival outcomes and downstaging to surgery in selected patients in a real-world setting further strengthens our confidence in the role of OncoSil in the treatment of unresectable locally advanced pancreatic cancer."
Dr Enrique Vázquez Sequeiros, who presented the interim analysis, said, "Presenting the first interim analysis of the OSPREY Registry at ESGE Days 2026 is an important milestone in demonstrating the real-world potential of the OncoSil Device for patients with unresectable locally advanced pancreatic cancer. These multicentre European data show that treatment with OncoSil alongside gemcitabine-based chemotherapy is safe, well-tolerated, and associated with encouraging disease control, downstaging to surgery in selected patients, and promising overall survival outcomes. We believe these findings further support the role of OncoSil as a valuable addition to the treatment pathway for this highly challenging disease."